Dallah Healthcare
دله الصحيةTechnical Analysis & Signals
Dallah Health stock is trending downward with increasing selling pressure.
Technical Analysis
The technical analysis of Dallah Health stock shows a clear downward trend, with the price falling to 112.0 SAR. Indicators like RSI at 33.2 and negative MACD Hist suggest weakness in buying momentum.
Support & Resistance Levels
The main support level is at 110.4 SAR, while the nearby resistance is at 115.0 SAR. A break below the support level may lead to further price declines.
Volume Analysis
Volume data is not provided, but an increase in trading volume is expected if the downward trend continues. Increased volume may indicate new investors entering or existing positions being liquidated.
Fundamental Factors
The P/E ratio of Dallah Health stock is 20.8, indicating a relatively high valuation. The dividend yield at 1.73% may attract some investors, despite current pressures.
Risk Factors
Potential risks include deteriorating financial performance, market volatility, and general economic pressures. These factors may negatively impact the stock price in the future.
Recommendation
Disclaimer: This analysis is for educational purposes only and does not constitute investment advice. Investors are advised to conduct their own research before making any investment decisions.
Automated analysis is based on historical data and technical indicators and may not reflect future market conditions.
Financial Fundamentals
Price Data
Price Chart - Dallah Healthcare
4004Technical Analysis
Moving Averages
Momentum Indicators
Bollinger Bands
Below Lower BandTrend Strength (ADX)
Moderate TrendFinancial Summary
Valuation
- Market Cap
- 11.32B
- P/E Ratio
- 20.80
- P/B Ratio
- 2.80
- EPS (Earnings/Share)
- 5.39
Profitability
- Revenue
- 4.07B
- Net Income
- 538.27M
- Return on Equity (ROE)
- +10.00%
- Shares Outstanding
- 101.10M
Balance Sheet
- Total Assets
- N/A
- Total Debt
- 3.93B
- Debt/Equity
- 0.95
- Free Float %
- +43.1%
Dividends & Margins
- Dividend Yield
- +1.73%
- Dividend/Share
- 2.00
- Book Value
- 40.00
Financial data extracted from published quarterly reports. All values in SAR unless otherwise stated.
Historical Financial Data
4 years| Year | Revenue | Net Income | Total Assets | Total Debt | EPS |
|---|---|---|---|---|---|
| 2024 | 3.21B +8.9% | 471.20M +30.8% | 6.61B +6.0% | 2.02B +2.5% | 4.66 +30.9% |
| 2023 | 2.94B +18.3% | 360.12M +31.2% | 6.24B +26.9% | 1.97B -0.2% | 3.56 +31.4% |
| 2022 | 2.49B +18.2% | 274.46M +6.1% | 4.92B +5.9% | 1.98B +4.7% | 2.71 +5.9% |
| 2021 | 2.11B | 258.60M | 4.65B | 1.89B | 2.56 |
Historical data sourced from Yahoo Finance and may differ from official audited financial reports.
Price Forecast
These forecasts are based on technical analysis and AI and do not constitute investment advice. Past performance does not guarantee future results.
News & Events
Tadawul-listed firms likely to announce dividends in March
Completion of Kingdom Hospital acquisition boosts Dallah Healthcare's strong presence in Riyadh
Dallah Healthcare completes Care Shield acquisition
Dallah signs deal with Maharah subsidiary to buy stake in Care Shield for SAR 434.3M
AlJazira Capital sets potential changes in MSCI February index review
Ubhar Capital issues Q4 2025 earnings forecasts
Saudi healthcare sector in Q4 2025: Key events likely to impact performance
Key events to drive Saudi-listed firms' performance in Q4 2025
News source: Argaam (argaam.com)
Sector Comparison
| Symbol | Name | Price | Change% |
|---|---|---|---|
| 4013 | Dr. Sulaiman Al Habib | 224.60 SAR | |
| 4002 | Mouwasat | 66.50 SAR | |
| 4004 | Dallah Healthcare | 112.00 SAR | |
| 4017 | Fakeeh Care | 36.00 SAR | |
| 4018 | Almoosa | 129.50 SAR | |
| 4005 | CARE | 103.30 SAR | |
| 4019 | SMC Healthcare | 17.60 SAR | |
| 4007 | Alhammadi | 25.32 SAR |
Dividend History
Dividend data from Tadawul records. All amounts in SAR. Estimated yield calculated based on year-end price.
Ownership Structure
Data source: Yahoo FinanceLast updated: 2026-05-11
Risk Assessment
Risk Factors
Average True Range 2.3% of stock price
Trading volume near or above average
P/E ratio 20.8
Debt-to-equity ratio 0.95
ADX indicator at 25
High volatility and financial pressures requiring careful monitoring
This assessment is automated based on quantitative data and does not constitute investment advice. Please consult a licensed financial advisor before making investment decisions.
FAQ
1 What is Dallah Healthcare stock price today?
Dallah Healthcare (4004) stock price today is 112.00 SAR, declining by -3.11% compared to the previous session close. The 52-week price range is between 89.62 SAR and 156.09 SAR.
2 What is Dallah Healthcare stock valuation?
The automated analysis signal for Dallah Healthcare is "Strong Sell" with 75% confidence. The P/E ratio is 20.8. The P/B ratio is 2.80.
3 Is Dallah Healthcare Shariah-compliant?
Yes, Dallah Healthcare (4004) is Shariah-compliant according to the latest lists approved by relevant Shariah authorities.
4 What are Dallah Healthcare dividend distributions?
Dallah Healthcare has a dividend yield of 1.73%, with an estimated annual dividend of 2.00 SAR per share.
5 What is Dallah Healthcare weekly performance?
Dallah Healthcare performance over different time periods: weekly change -7.97%, monthly -17.95%, and year-to-date -10.16%. The stock is currently trading with a volume of 222,267 shares.
6 What is the target level for Dallah Healthcare?
According to automated analysis for Dallah Healthcare: Short-term target (1-2 weeks): 108.00 SAR. Support level: 110.40 SAR. Resistance level: 115.00 SAR. Note: These are automated analytical levels and do not constitute investment advice.
Disclaimer
The information provided on this page is for educational and analytical purposes only and does not constitute investment advice or a recommendation to buy or sell. Past performance does not guarantee future results. All investments involve risk including loss of capital. Please consult a licensed financial advisor before making any investment decisions.
Automated analysis relies on historical data and technical indicators and may not reflect future market conditions.